Company intelligence / Profile preview

Zentopharm

Ownership: Private
Development stage: Phase 3

Overview

Zenopharm developed an orally bioavailable selective estrogen receptor downregulator ("ZB") with superior preclinical bioavailability and efficacy compared to fulvestrant. As of the last available update in 2018, the company was preparing IND-enabling studies to support first-in-human clinical trials targeting advanced/metastatic breast cancer patients who have progressed after prior endocrine therapies.[3]

Therapeutic areas: Oncology
Modalities: Small moleculesspecifically oral SERDs (Selective Estrogen Receptor Downregulators)
Industry: Biotech

Drug pipeline

1 asset

fosmidomycin + clindamycin

Phase 3

Indications: Malaria

Partnerships

Avista Pharma Solutions for GMP manufacturingCovance for nonclinical development plan implementation[3]

Beyond the preview

Go deeper on Zentopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zentopharm.

Explore the full profile